

Vitae Pharmaceuticals Announces Pricing of Follow-on Public Offering of Common Stock

January 23, 2015 7:20 AM ET

FORT WASHINGTON, Pa., Jan. 23, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (Nasdaq:VTAE), a clinical stage biotechnology company, today announced the pricing of its follow-on public offering of 3,000,000 shares of its common stock at \$11.90 per share. All shares of common stock to be sold in the offering are being offered by Vitae. Vitae has also granted the underwriters a 30-day option to purchase up to an additional 450,000 shares of common stock.

The offering is expected to close on or about January 28, 2015, subject to customary closing conditions.

Stifel, BMO Capital Markets and Piper Jaffray & Co. are acting as joint book-running managers and JMP Securities and Wedbush PacGrow Life Sciences are acting as co-managers for the offering.

A registration statement relating to the shares to be sold in the offering has been filed with the Securities and Exchange Commission, and was declared effective on January 22, 2015. The offering is being made only by means of a prospectus. Copies of the prospectus related to the offering may be obtained from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, telephone: (415) 364-2720, email: syndprospectus@stifel.com; or from BMO Capital Markets Corp., 3 Times Square, New York, NY 10036, Attention: Equity Syndicate Department, telephone: (800) 414-3627, email: bmo prospectus@bmo.com; or from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, telephone: (800) 747-3924, email: prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

CONTACT: Investors:
Vitae Pharmaceuticals, Inc.
Richard S. Morris, CPA
Chief Financial Officer
(215) 461-2000
rmorris@vitaerx.com

or

Westwicke Partners
John Woolford
(443) 213-0506
john.woolford@westwicke.com

or

Media:
6 Degrees PR
Tony Plohoros
(908) 940-0135
tplohoros@6degreespr.com

 [Vitae Logo](#)

Vitae Pharmaceuticals